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“There needs to be a
cultural shift in the
more formal frame-





being above the call
of duty to being a
moral obligation
for everyone to do
his/her part”All of us are excited to hear the results of the latest clinical trials that may change practice
and improve outcomes. Are we equally enthusiastic when it comes to acquiring this useful
information? Experimental science is hard work but does not require volunteers to become subjects
or investigators to invite people to become subjects. Clinical research, in contrast, brings into play
the unavoidable interaction between individual autonomy and the common good. John Locke, in
the 17th century, and Immanuel Kant, in the 18th century, spoke to the rights of the individual
and their primacy. In the same period, Thomas Hobbes, and later Jean-Jacques Rousseau,
developed the concept of the social contract, whereby participation of the individual beneﬁts the
community. Viewed in the context of clinical research, are the inalienable rights of the individual
in conﬂict with the common good of the community? The current prevailing view is that
participation in clinical research is beyond the call of duty, and individuals who agree to participate
are unusual and therefore few. Opting in is the norm. Should opting out be considered? Has the
pendulum between individual rights and community beneﬁts swung too far in the direction of
individual liberties? There is no argument that all clinical research must include consent that fully
informs subjects of what is being proposed and that any participation is voluntary. However, are we
impeding the advancement of clinical knowledge and the beneﬁt to the community by not making
participation in clinical research normal rather than unusual? Some disciplines and institutions
practice this approach much more than others. Oncology is the prime example, in which clinical
trials are often the norm, but it is less the case in cardiovascular medicine.
Is there really a conﬂict between the individual and the community? I think not, because
knowledge of beneﬁt, or lack thereof, although certainly of value to the community, also beneﬁts
the individuals who make up that community, including sometimes the subjects themselves who
volunteer for trials, or their families. Although duty does not mean legal obligation, writing on this
subject, a group from the Department of Bioethics at the National Institutes of Health concluded,
“There needs to be a cultural shift in the more formal framework that is brought to participation in
research.from participation in biomedical research being above the call of duty to being a moral
obligation for everyone to do his/her part” (1).
If patients have a duty to participate in research, what about the physicians caring for those
patients? The ﬁrst obligation is clearly to the individual patient, but if the results of clinical trials
are so interesting and potentially important to the rest of our patients, what is our duty to
encourage participation of the appropriate patients in research? Of course, there are many other
barriers to clinical research. One we discussed in a prior Editor’s Page is the uneven reimbursement
approval from the Centers for Medicare and Medicaid Services for medical device research that has
been provisionally cleared by the U.S. Food and Drug Administration (2). Another impediment
are the unreasonable time and work commitments of physicians in informing patients and
discussing options. Clinical trials that impose signiﬁcant economic hardships on physicians
will have a hard time recruiting. It is concerning that many clinical trials are successfully
enrolling patients only from countries with inadequate compensation for physicians’ clinical work.
Economics aside (and it is hard to put them aside), physicians have no less duty than patients
to contribute to the medical knowledge to be gained from important clinical trials.
A word about the quality of trials for which patients request to volunteer: Not every trial is
worthy of patients’ and physicians’ duty to participate. Some trials have little game-changing
potential and are designed to support minor changes in the approval of devices, procedures, or
therapies. Trial methods will not be understood by most subjects, but physicians participating in
a trial should understand whether the methods are sufﬁcient to answer the questions posed. Some
trials will not rise to the level of convincing patients or physicians that it is their moral duty to
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451contribute to the answer. Applying time and energy to
answer the important questions will always be more
effective and satisfying.
As we crowd into the main arena of the America
College of Cardiology Scientiﬁc Sessions, the Amer-
ican Heart Association Scientiﬁc Sessions, the
Transcatheter Cardiovascular Therapeutics Annual
Meeting, or the European Society of Cardiology or
EuroPCR meeting to hear the late-breaking trial
results, or as we digest the published reports, we
should be thankful to those patients and physicians
who have made the ﬁndings possible. But we should
also be concerned that we have not done enough to
ensure timely completion of other clinical trials that
will inﬂuence effective and efﬁcient care. As “incon-
venient” as it may sometimes be, helping our patientsdischarge their duty to participate in the trials that will
lead to beneﬁt for all is our duty as well.Address correspondence to:
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